Type 1 Diabetes

By Guest Writer David Kliff, Diabetic Investor: As we were getting ready to disembark the plane when it arrived in Lisbon I asked a long-term consultant to the diabetes industry why he comes to EASD. “I like to come here because what they have here will show up in our country in two years” was his response. Given what we witnessed at EASD there isn’t much to look forward to in 2019.

Trial results promising, but DKA still a concern with use of new once-daily pills.

Philadelphia youth see rise in diagnosis; especially for African Americans, by 70%.

The results of the REMOVAL study were presented at the 2017 European Association for the Study of Diabetes (EASD) in Lisbon

Real-time monitoring produces significant long-term improvement in HbA1c.

Study examined effectiveness of CGM on maternal glucose control and obstetric and neonatal health outcomes.

Addition to insulin therapy helped reduce hemoglobin A1c levels, researchers reported.

T1D patients with certain characteristics would benefit the most from reimbursement of blood glucose test strips.

Carotid ultrasound shows atherosclerotic disease is not just a concern for patients with type 1 and type 2 diabetes, but LADA as well.

The evolution of metformin therapy through the decades.